Background: Combination analgesics provide more effective pain relief for a broader spectrum of pain. This research examines the possible potentiation of the analgesic effect of different classes of antidepressants when combined with aspirin in thermal model of pain using Albino mice.
Methods: Different groups of six animals each were injected intraperitoneally by different doses of aspirin (50, 100, or 200 mg/kg), imipramine (2.5, 7.5, 15 or 30 mg/kg), fluoxetine (1.25, 2.5, 5 or 7.5 mg/kg), mirtazapine (1.25, 2.5, or 5 mg/kg) and a combination of a fixed dose of aspirin (100 mg/kg) with the different doses of the three antidepressants. One hour later the analgesic effect of these treatments were evaluated against thermally induced pain. All data were subjected to statistical analysis using unpaired Student's t-test.
Results: Aspirin had no analgesic effect in thermally induced pain. The three selected antidepressants produced dose dependent analgesia. The addition of a fixed dose of aspirin to imipramine significantly increased the reaction time (RT) of the lowest dose (by 23%) and the highest dose (by 20%). The addition of the fixed dose of aspirin to fluoxetine significantly increased RT by 13% of the dose 2.5 mg/kg. Finally, the addition of the fixed dose of aspirin significantly potentiated the antinociceptive effect of the different doses of mirtazapine (RT was increased by 24, 54 and 38% respectively).
Conclusion: Combination of aspirin with an antidepressant might produce better analgesia, increasing the efficacy of pain management and reduces side effects by using smaller doses of each drug.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332043 | PMC |
http://dx.doi.org/10.3402/ljm.v7i0.17251 | DOI Listing |
Int J Pharm
January 2025
University of Applied Sciences and Arts Northwest. Switzerland, School of Life Sciences, Institute of Pharma Technology, Hofackerstr. 30 CH-4132 Muttenz, Switzerland. Electronic address:
In recent years, deep eutectic solvents (DESs) with their outstanding solubilization properties have emerged as strong candidates for oral enabling formulations of poorly soluble drugs. This study explores the use of drug-based therapeutic DESs (THEDESs) to solubilize a poorly soluble compound with the aim of providing a fixed-dose combination of two complementary therapeutic agents. Specifically, potential anticancer effects of ibuprofen (IBU) are harnessed in a novel type of THEDES to dissolve higher amounts of abiraterone acetate (AbAc), an antitumor agent.
View Article and Find Full Text PDFPhys Med Biol
January 2025
Radiotherapy and Radiosurgery department, Iatropolis Clinic, 54 Ethnikis Antistaseos ave., Athens, Attica, 15231, GREECE.
Using the concept of biologically effective dose (BED), the effect of sublethal DNA damage repair (SLR) on the bio-efficacy of prolonged radiotherapy treatments can be quantified (BED). Such treatments, lasting more than 20 min, are typically encountered in stereotactic radiosurgery (SRS) applications using the CyberKnife (CK) and Gamma knife systems. Evaluating the plan data from 45 Vestibular Schwannoma (VS) cases treated with single fraction CK-SRS, this work demonstrates a statistically significant correlation between the marginal BEDSLR delivered to the target (m-BEDSLR) and the ratio of the mean collimator size weighted by the fraction of total beams delivered with each collimator ((_w^m)Cs), to the tumor volume (Tv).
View Article and Find Full Text PDFAnn Rheum Dis
January 2025
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address:
Objectives: The usefulness of methotrexate-polyglutamates (MTX-PGs) concentration for management of rheumatoid arthritis has been debated. We aimed to clarify the association of MTX-PGs concentration with efficacy and safety in MTX-naïve patients initiating MTX in a prospective interventional clinical trial.
Methods: The MIRACLE trial enrolled 300 MTX-naïve patients.
Objective: To summarize antiretroviral therapy (ART) use in the setting of end-stage kidney disease (ESKD).
Design: Cross-sectional analysis.
Methods: Descriptive analysis of ART regimens and dose of nucleoside/nucleotide reverse-transcriptase inhibitors (NRTI) in people with HIV and ESKD (dialysis, kidney transplantation, or estimated glomerular filtration rate (eGFR) <15 mL/min/1.
Eur Clin Respir J
January 2025
Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities of TDM for ETI performed in a person with cystic fibrosis and refractory pulmonary disease. Utilising National Association of Testing Authorities (NATA) accredited assays and target considerations published by the Therapeutic Goods Administration (TGA), Australia, ETI plasma concentration variability was monitored over the course of an acute admission with added complexity from an antibiotic regimen including rifabutin, a moderate cytochrome P450 3A (CYP3A) inducer, and clofazimine, a mild CYP3A inhibitor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!